10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval G. Daver, Tapan M. Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C. Issa, Guillermo Montalban-Bravo, Nicholas J. Short, Musa Yilmaz, Prithviraj Bose, Elias J. Jabbour, Koichi Takahashi, Jan A. Burger, Guillermo Garcia-Manero, Nitin JainSteven M. Kornblau, Philip A. Thompson, Zeev Estrov, Lucia Masarova, Koji Sasaki, Srdan Verstovsek, Alessandra Ferrajoli, William G. Weirda, Sa A. Wang, Sergej Konoplev, Zhining Chen, Sherry A. Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S. Welch, Hagop M. Kantarjian, Marina Y. Konopleva

Research output: Contribution to journalArticlepeer-review

104 Scopus citations

Fingerprint

Dive into the research topics of '10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences